155 related articles for article (PubMed ID: 5513972)
1. Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-aminoimidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Biochem Pharmacol; 1970 Jun; 19(6):2043-51. PubMed ID: 5513972
[No Abstract] [Full Text] [Related]
2. Disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, a new antitumor agent.
Housholder GE; Loo TL
J Pharmacol Exp Ther; 1971 Nov; 179(2):386-95. PubMed ID: 5133607
[No Abstract] [Full Text] [Related]
3. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
4. Fate of the ring moiety of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in mammalian cells.
Saunders PP; Chao LY
Cancer Res; 1974 Oct; 34(10):2464-9. PubMed ID: 4472112
[No Abstract] [Full Text] [Related]
5. Elevated inary excretion of 4-aminoimidazole-5-carboxamide in patients after intravenous injection of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide.
Housholder GE; Loo TL
Life Sci; 1969 May; 8(9):533-6. PubMed ID: 5791705
[No Abstract] [Full Text] [Related]
6. N-demethylation the antineoplastic agent4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide by rats and man.
Skibba JL; Beal DD; Ramirez G; Bryan GT
Cancer Res; 1970 Jan; 30(1):147-50. PubMed ID: 5441073
[No Abstract] [Full Text] [Related]
7. Metabolism of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in human and animal tumor tissue.
Mizuno NS; Humphrey EW
Cancer Chemother Rep; 1972 Aug; 56(4):465-72. PubMed ID: 5081589
[No Abstract] [Full Text] [Related]
8. Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.
Loo TL; Luce JK; Jardine JH; Frei E
Cancer Res; 1968 Dec; 28(12):2448-53. PubMed ID: 5728154
[No Abstract] [Full Text] [Related]
9. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel CL; Denham C; Waalkes TP; DeVita VT
Cancer Res; 1970 Jun; 30(6):1651-7. PubMed ID: 5457935
[No Abstract] [Full Text] [Related]
10. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel CL; DeVita VT; Denham C; Foley HT; Field RB; Carbone PP
Cancer Chemother Rep; 1971 Apr; 55(2):159-65. PubMed ID: 5118685
[No Abstract] [Full Text] [Related]
11. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
Carter SK; Friedman MA
Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
[No Abstract] [Full Text] [Related]
12. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
Kingra GS; Comis R; Olson KB; Horton J
Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
[No Abstract] [Full Text] [Related]
13. Mechanism of action of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in mammalian cells in culture.
Gerulath AH; Loo TL
Biochem Pharmacol; 1972 Sep; 21(17):2335-43. PubMed ID: 4675028
[No Abstract] [Full Text] [Related]
14. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
Gerner RE; Moore GE
Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
[No Abstract] [Full Text] [Related]
15. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
Kline I; Woodman RJ; Gang M; Venditti JM
Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
[No Abstract] [Full Text] [Related]
16. Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda.
Vogel CL; Comis R; Ziegler JL; Kiryabwire JW
Cancer Chemother Rep; 1971 Apr; 55(2):143-9. PubMed ID: 5118684
[No Abstract] [Full Text] [Related]
17. Adaptation of a colorimetric determination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) and 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) to blood.
Field RB; Hoffman G; Waravdekar VS; Kline I
Cancer Chemother Rep; 1969 Jun; 53(3):199-202. PubMed ID: 4980814
[No Abstract] [Full Text] [Related]
18. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
[No Abstract] [Full Text] [Related]
19. Role of 4-diazoimidazole-5-carboxamide in the action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4-(5)carboxamide in Bacillus subtilis.
Saunders PP; Schultz GA
Biochem Pharmacol; 1972 Aug; 21(15):2065-76. PubMed ID: 4630320
[No Abstract] [Full Text] [Related]
20. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
Einhorn LH; McBride CM; Luce JK; Caoili E; Gottlieb JA
Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
[No Abstract] [Full Text] [Related]
[Next] [New Search]
